DK0462187T3 - Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors - Google Patents

Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors

Info

Publication number
DK0462187T3
DK0462187T3 DK90904636.9T DK90904636T DK0462187T3 DK 0462187 T3 DK0462187 T3 DK 0462187T3 DK 90904636 T DK90904636 T DK 90904636T DK 0462187 T3 DK0462187 T3 DK 0462187T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
pharmaceutical composition
papilloma virus
induced tumors
Prior art date
Application number
DK90904636.9T
Other languages
Danish (da)
Inventor
Guerrino Meneguzzi
Richard Lathe
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK0462187T3 publication Critical patent/DK0462187T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention concerns the use in a pharmaceutical composition for the prevention and treatment of papillomavirus-induced tumours, in particular the HPV-16 virus, of a recombinant poxvirus comprising an heterologous DNA sequence coding at least for the essential region of a non-structural papillomavirus protein as well as the regulation elements ensuring its expression in the higher cells. More particularly, it concerns the E5, E6, E7 proteins of the HPV-16 virus.
DK90904636.9T 1989-03-06 1990-03-06 Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors DK0462187T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8902897A FR2643817B1 (en) 1989-03-06 1989-03-06 PHARMACEUTICAL COMPOSITION, USEFUL AS A PREVENTIVE OR CURATIVE AGAINST TUMORS INDUCED BY PAPILLOMAVIRUS

Publications (1)

Publication Number Publication Date
DK0462187T3 true DK0462187T3 (en) 1993-10-18

Family

ID=9379397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90904636.9T DK0462187T3 (en) 1989-03-06 1990-03-06 Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors

Country Status (9)

Country Link
EP (1) EP0462187B1 (en)
JP (1) JP2926270B2 (en)
AT (1) ATE91630T1 (en)
CA (1) CA2050304C (en)
DE (1) DE69002325T2 (en)
DK (1) DK0462187T3 (en)
ES (1) ES2058898T3 (en)
FR (1) FR2643817B1 (en)
WO (1) WO1990010459A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
EP0772689B1 (en) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retroviral vectors having a reduced recombination rate
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
FR2751879B1 (en) * 1996-07-30 1998-10-30 Transgene Sa PHARMACEUTICAL COMPOSITION AGAINST TUMORS AND PAPILLOMAVIRUS INFECTIONS
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
CA2441947C (en) 2001-03-23 2014-05-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreactive peptides
ATE500267T1 (en) 2003-07-21 2011-03-15 Transgene Sa MULTIFUNCTIONAL CYTOKINE
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
WO2008092854A2 (en) 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
DK2382474T3 (en) 2009-01-20 2015-04-07 Transgene Sa SOLUBLE ICAM-1 as a biomarker FOR PREDICTION OF THERAPEUTIC RESPONSE
EP2411815B1 (en) 2009-03-24 2015-11-11 Transgene SA Biomarker for monitoring patients
BRPI1010512A2 (en) 2009-04-17 2016-03-15 Transgène S A "Ex vivo method for assessing the efficacy of a treatment involving the administration of an immunogenic composition to a patient, and use of activated t-lymphocyte levels (cd3 + cd69 +) as a biomarker"
EP2429579A1 (en) 2009-05-12 2012-03-21 Transgene SA Immortalized avian cell lines and use thereof
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (en) 2012-10-02 2020-04-11 法商傳斯堅公司 Virus-containing formulation and use thereof
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2016087457A1 (en) 2014-12-01 2016-06-09 Transgene Sa Stable liquid vaccinia virus formulations
AU2018270375A1 (en) 2017-05-15 2019-10-31 Bavarian Nordic A/S Stable virus-containing composition
JP2020519666A (en) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Stable virus-containing composition
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As Compositions improving poxvirus stability

Also Published As

Publication number Publication date
WO1990010459A1 (en) 1990-09-20
CA2050304C (en) 2002-01-22
EP0462187B1 (en) 1993-07-21
ATE91630T1 (en) 1993-08-15
FR2643817A1 (en) 1990-09-07
JP2926270B2 (en) 1999-07-28
JPH05503282A (en) 1993-06-03
DE69002325T2 (en) 1993-12-02
DE69002325D1 (en) 1993-08-26
CA2050304A1 (en) 1990-09-07
EP0462187A1 (en) 1991-12-27
FR2643817B1 (en) 1993-12-17
ES2058898T3 (en) 1994-11-01

Similar Documents

Publication Publication Date Title
DK0462187T3 (en) Pharmaceutical composition which can be used for the prevention or treatment of papilloma virus-induced tumors
DE58906121D1 (en) Recombinant vaccinia virus MVA.
DE69535018D1 (en) PAPILLOMA VIRUS VACCINE
DE69435332D1 (en) Preparation of human papillomavirus envelope protein and virus-like particles
BRPI0412845A (en) herpes virus, use of a virus, pharmaceutical composition, and method of treating a tumor in an individual in need thereof
LU91387I2 (en) CERVARIX - The combination of particles similar to HPV16 and HPV18
ES2191663T3 (en) RECOMBINING VIRUS OF THE PORCINE VIRUELA.
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
DK1090033T4 (en) Particles of HCV envelope proteins: Use for vaccination
DE68929467D1 (en) HIV-2 variants
KR970701062A (en) Paramunity Inducers Based on Combination of Poxvirus Components, Methods of Making the Same, and Uses in the Agents
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
UA82998C2 (en) Expression of genes in modified vaccinia virus ankara using bovine poxvirus promotor аті
DK0512011T3 (en) Blood factors produced by recombinant DNA technology, method of expression of the blood factors, and vaccinia virus recombinants used in the method
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
DE69736779D1 (en) COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES
DK0781344T3 (en) Newly known implant and novel vector for the treatment of acquired diseases
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
AR248047A1 (en) Vaccines based on modified bovine herpesvirus type i